SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.

Autor: C, Barone F, A, Irving E, M, Ray A, C, Lee J, S, Kassis, S, Kumar, M, Badger A, F, White R, J, McVey M, J, Legos J, A, Erhardt J, H, Nelson A, H, Ohlstein E, J, Hunter A, K, Ward, R, Smith B, L, Adams J, A, Parsons A

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; February 2001, Vol. 296 Issue: 2 p312-21, 10p

Endothelin B receptor modulates inflammatory pain and cutaneous inflammation.

Autor: E, Griswold D, A, Douglas S, D, Martin L, G, Davis T, L, Davis, Z, Ao, A, Luttmann M, M, Pullen, P, Nambi, W, Hay D, H, Ohlstein E

Publikováno v: Molecular Pharmacology; October 1999, Vol. 56 Issue: 4 p807-12, 6p

Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells.

Autor: P, Sung C, J, Arleth A, C, Eichman, A, Truneh, H, Ohlstein E

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; November 1997, Vol. 283 Issue: 2 p910-7, 8p

Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog.

Autor: N, Willette R, H, Ohlstein E, P, Mitchell M, F, Sauermelch C, R, Beck G, A, Luttmann M, W, Hay D

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; February 1997, Vol. 280 Issue: 2 p695-701, 7p